TYRA
Tyra Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.65
+15.25%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.2x
Market Cap
$1.71B
MomentumView details →
1D Return
+15.25%
YTD Return
+8.18%
RSI (14)
57.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.2x
Market Cap
$1.71B
RSI (14)
57.3
MomentumView details →
1D Return
+15.25%
YTD Return
+8.18%
SummaryUpdated Jun 1, 2026
Tyra Biosciences, Inc. (NASDAQ:TYRA) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Carlsbad, California. The company went public in September 2021 and focuses on developing innovative cancer therapies designed to overcome tumor resistance mechanisms that limit the effectiveness of existing treatments. Tyra specializes in precision oncology, utilizing its proprietary SNAP platform to design targeted therapies against specific genetic mutations that drive cancer growth and resistance.
Similar companies
Latest newsMore news →
Tyra Biosciences appointed Jonathan Day as EVP, Clinical Development to advance its skeletal dysplasia strategy.31d agoTyra Biosciences reported financial results for the second quarter ended June 30, 2026, with cash, cash equivalents and marketable securities of $353.9 million and a runway into the second half of 2028.31d ago